Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy Adds The Netherlands Cancer Institute-Antoni van

 Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy Adds
       The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital

  PR Newswire

  AMSTERDAM, April 20, 2013

      - Dutch clinic joins group dedicated to developing next-generation
           radiotherapy innovation for treatment of cancer patients

AMSTERDAM, April 20, 2013 /PRNewswire/ --Elekta (NSE: EKTAb) and Royal
Philips Electronics (NYSE: PHG, AEX: PHIA) announced today that The
Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL,
Amsterdam, the Netherlands) has signed an agreement to join a research group
to advance the development of ground-breaking image-guided treatment
technology for cancer care. The technology merges radiation therapy and
magnetic resonance imaging (MRI) technology in a single system. NKI-AVL is the
third member of the research consortium, which will comprise leading radiation
oncology centers and clinicians, and already includes the University Medical
Center Utrecht and The University of Texas MD Anderson Cancer Center.

Uniting state-of-the-art MRI with a cutting edge radiation therapy system -
thus creating an MRI-guided radiation therapy system - will provide physicians
with exceptional images of a patient's soft tissues and tumor during radiation
therapy. This breakthrough innovation also aims to permit clinicians to adapt
treatment delivery in real time for the most precise cancer treatments
possible.

"MRI has steadily revolutionized healthcare since its introduction nearly
three decades ago, giving clinicians unparalleled views of soft tissues and
pathology. Merging this diagnostic capability with the capacity to also treat
disease in the same frame of reference could dramatically improve cancer
management," says Tomas Puusepp, Elekta President and CEO. "The other
consortium members at Elekta, Philips, University Medical Center Utrecht and
MD Anderson are delighted that NKI-AVL- an internationally renowned medical
center - has joined us in this important effort."

Prof. Marcel Verheij, Head of the Radiotherapy Division at NKI-AVL, said:
"MRI-guided radiotherapy allows optimal imaging and will therefore improve the
accuracy of our treatment delivery. Building on our experience with Cone Beam
CT-guidance we are highly motivated to collaborate within the research
consortium and contribute to the implementation of MRI-guided adaptive
radiotherapy."

"This research exemplifies the essential role that imaging plays in the
development of more targeted treatments for cancer," said Gene Saragnese CEO
Imaging Systems at Philips Healthcare. "The Netherlands Cancer
Institute-Antoni van Leeuwenhoek Hospital has played a crucial role in the
software development for CT-guided radiation therapy a decade ago, and this
expertise complements the skills that we already possess in this research
consortium."

Prior to the establishment of the research consortium, Elekta, Philips and the
University Medical Center Utrecht built and tested a prototype system that
integrates a linear accelerator and a 1.5 Tesla MRI system. The success of
these efforts enabled the project to move to the next phase of development and
testing by the growing select group of consortium partners.

Radiation therapy and medical imaging already play an essential role in
treatment planning, delivery and after care, and are proven, cost-effective
and safe methods for the treatment of individuals with cancer. Radiotherapy is
a critical modality for cancer treatment, either as a frontline treatment or
used with other modalities, such as chemotherapy. The procedure involves
identifying cancerous tissue and irradiating it with high-energy radiation
beams in a way that maximizes sparing of healthy tissues near the tumor. 

The integrated MRI-guided radiation therapy system is in development and not
available for sale.

For further information, please contact: Johan Andersson, Director, Investor
Relations, Elekta ABTel: +46-702-100-451, email: johan.andersson@elekta.com 
 Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management,
Elekta Tel: +1-770-670-2447, email: michelle.joiner@elekta.com Time zone: ET:
Eastern Time

Steve Klink, Philips Corporate CommunicationsTel: +31-20-5977415, email:
steve.klink@philips.com

About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow
enhancing software systems across the spectrum of cancer care. Stretching the
boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare
providers and patients, Elekta aims to improve, prolong and even save patient
lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,400 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com
.

About Royal Philips Electronics

Royal Philips Electronics (NYSE: PHG, AEX: PHIA) is a diversified health and
well-being company, focused on improving people's lives through meaningful
innovation in the areas of Healthcare, Consumer Lifestyle and Lighting.
Headquartered in the Netherlands, Philips posted 2012 sales of EUR 24.8
billion and employs approximately 118,000 employees with sales and services in
more than 100 countries. The company is a leader in cardiac care, acute care
and home healthcare, energy efficient lighting solutions and new lighting
applications, as well as male shaving and grooming and oral healthcare. News
from Philips is located at www.philips.com/newscenter .

Website: http://www.elekta.com
 
Press spacebar to pause and continue. Press esc to stop.